Proximagen is dedicated to discovering and developing innovative therapies to improve the lives of patients with neurodegenerative diseases.
From Research to Developing Therapies:
Proximagen's team of scientists is continually working to identify
new opportunities to meet the health care challenges of patients
with neurodegenerative disease. Building on over 25 years of
leadership in neurodegenerative research, Proximagen utilises its experience
to bring the best of academic research in to the commercial environment of the
pharmaceutical industry and biotechnology field.
Proximagen has long standing experience of the development of symptomatic based treatments for neurodegenerative treatments together with the utilisation of model systems for the study of cell death mechanisms for the development of neuroprotective and/or neurorestorative treatment strategies.
In addition to the discovery programme in Proximagen's own laboratories, the
company also participates in leading edge research conducted by leading
academics and university and medical science centres worldwide, and works
collaboratively with its partners to develop innovative therapies.
Proximagen is committed to creating, recognizing, and acting on
scientific breakthroughs to develop the next generation of therapies for
improving the quality of life of patients with neurodegenerative diseases.
Please visit the our resource library to learn about recent Proximagen publications.
